An observational study in Cerebrovascular Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by Beijing Tiantan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, 1 of them phase 3. Cerebrovascular Disorders · Beijing Tiantan Hospital.
Among the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital, this one is one of 5 that started in 2025, is one of 5 observational ones, and was the 8th registered.
450 studies on the registry are indexed under Cerebrovascular Disorders; 126 are open to participants now.
Browse Cerebrovascular Disorders studies →10 of the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 1–80
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 50–75 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 6–90 · Healthy volunteers
By country, each count listing its studies:
Of the 94 Cerebrovascular Disorders studies recruiting now, 54 (57%) set no upper age limit and 12 (13%) stop at 75 or younger; 10 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 447 across 146 observational studies indexed under Cerebrovascular Disorders.
Median enrollment 328 across the 7 interventional studies, 1,000 across the 5 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
1 of the studies in Cerebrovascular Disorders by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06925178Beijing Tiantan HospitalMulti-Modality Imaging Standard Cohort Of Cerebrovascular Disease | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to establish a multi-center and multi-modality imaging standard cohort of cerebrovascular disease, analyze the potential mechanisms affecting the prognosis of cerebrovascular disease based on a variety of imaging methods, and explore potential therapeutic targets.
Cerebrovascular diseases are major diseases that pose a serious threat to human health and life, and have become the leading cause of death from disease among Chinese residents. Despite the best medical or surgical treatment options, many patients still suffer from functional disabilities, imposing a heavy burden on families and society. Identifying the complex and delicate changes in brain neural activity, blood flow, oxygenation, and metabolism following the occurrence of cerebrovascular diseases can not only explore the potential mechanisms underlying poor functional prognosis, but also provide a scientific basis for targeted treatment strategies. This study is a consecutive, multicenter, prospective registration study that recruits approximately 800 patients with cerebrovascular diseases (both hemorrhagic and ischemic stroke) aged 18-80 years within 7 days of onset. The study collects baseline information and imaging data including head CT, MRI, TCD, fNIRS, and ophthalmic testing. The primary endpoint event was functional outcome 3 months (mRS score). Secondary outcomes were in-hospital complications (including stroke progression, recurrence, and mortality), cognitive disorder, functional outcomes, recurrent stroke, new vascular events, and all-cause death at 3, 6 and 12 months .
Patients aged 18-80 years old with acute cerebrovascular disease (hemorrhagic or ischemic stroke) within 7 days of onset; healthy adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The incidence of unfavorable functional outcome
Unfavorable functional outcome is defined as mRS Score 2-5. mRS is an efficient, reliable and simple scale to assess the recovery of neurological function and disability after stroke. The high score indicates the poor neurological recovery. The minimum score (0) means no symptoms at all. The maximum (6) means death.
Time frame: 3 month after enrollment
The incidence of in-hospital complications
In-hospital complications (including stroke progression, recurrence, and mortality).
Time frame: duration of hospital stay(about 1 week)
The incidence of unfavorable functional outcome
Unfavorable functional outcome is defined as the modified Rankin Scale (mRS) Score 2-5. mRS is an efficient, reliable and simple scale to assess the recovery of neurological function and disability after stroke. The high score indicates the poor neurological recovery. The minimum score (0) means no symptoms at all. The maximum (6) means death.
Time frame: 6 and 12 months after enrollment
The incidence of new vascular events
Including ischemic stroke, hemorrhagic stroke, myocardial infarction or vascular death.
Time frame: 3, 6 and 12 months after enrollment
The incidence of recurrent stroke
Stroke recurrence is defined as a new focal neurological impairment that was confirmed by neuroimaging, including both ischemic stroke and hemorrhagic stroke.
Time frame: 3, 6 and 12 months after enrollment
The incidence of all-cause death
An all-cause death is defined as a death from any cause.
Time frame: 3, 6 and 12 months after enrollment
The incidence of Cognitive impairment
Cognitive impairment is assessed using the MMSE and MOCA scales, with scores below 27 on the MMSE or below 26 on the MOCA indicating the presence of cognitive impairment.
Time frame: 3, 6 and 12 months after enrollment
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.
Of 77 non-industry observational studies under Cerebrovascular Disorders, half reached primary completion within 103 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 339. This study's planned 32 months is below that.
Counting every sponsor, half of 81 studies reached it within 101 months; a quarter within 57 and three quarters within 339.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.